Structural basis of MPL activation by thrombopoietin

Area of Science:

• Hematology
• Molecular Biology
• Structural Biology

Background:

• The thrombopoietin (TPO) receptor, Myeloproliferative leukemia protein (MPL), is essential for megakaryocyte development and platelet production.
• Mutations in MPL, TPO, or Janus kinase 2 (JAK2) are linked to various hematologic disorders, including myeloproliferative neoplasms.
• The precise molecular mechanism of TPO-driven MPL signaling remained incompletely understood.

Purpose of the Study:

• To elucidate the structural mechanisms underlying TPO-mediated MPL activation.
• To investigate the role of JAK2 in the TPO/MPL signaling complex.
• To provide insights into the constitutive activation of MPL signaling in disease states.

Main Methods:

• Cryo-electron microscopy (cryo-EM) was used to determine the structure of the mouse MPL ectodomain bound to TPO.
• Molecular dynamics (MD) simulations were employed to model the full-length human MPL/TPO complex and the ternary MPL/TPO/JAK2 complex.
• Functional activity assays were conducted to assess the relevance of MPL D4-D4 domain interactions.

Main Results:

• The cryo-EM structure revealed distinct low and high affinity binding sites between MPL and TPO, harboring several disease-associated mutations.
• MD simulations of the full-length complex highlighted the functional importance of MPL D4-D4 domain interactions.
• The ternary complex model elucidated JAK2 dimerization, identified key MPL interaction residues, and explained the V617F mutant's constitutive activation.
• The model also suggested mechanisms for JAK2 tyrosine kinase domain transphosphorylation.

Conclusions:

• This study provides a detailed structural and mechanistic understanding of the TPO/MPL/JAK2 signaling pathway.
• The findings illuminate how TPO binding induces MPL activation and subsequent JAK2 recruitment and activation.
• The insights gained offer a foundation for understanding disease-associated mutations and developing targeted therapies for hematologic disorders.